EligibleTrials

Clinical trials recruiting for Myasthenia Gravis

10
Recruiting trials
5
US states with sites
5
Countries
30%
Accept healthy volunteers

Phase breakdown

Early Phase 1 2Phase 1 2Not applicable 6

Drugs and treatments being studied

InterventionTrials
CD20/BCMA-directed CAR-T cells1
CT103A cells1
Cyclophosphamide1
Cyclophosphamide and fludarabine1
Fludarabine1
KITE-3631
UCAR T-cell1

Where trials are recruiting (top US states)

StateRecruiting trials
California3
New York1
South Dakota1
Utah1
Washington1

Top cities

Los Altos, California 1New York, New York 1Newport Beach, California 1Palo Alto, California 1Salt Lake City, Utah 1San Francisco, California 1Seattle, Washington 1Sioux Falls, South Dakota 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Myasthenia Gravis often also study these conditions. Each links to its own recruiting-trial list.

Multiple sclerosis 445Autoimmune Encephalitis 6Chronic Inflammatory Demyelinating Polyradiculoneuropathy 3Obesity 1512Neuromyelitis Optica Spectrum Disorder 5Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) 4Idiopathic Inflammatory Myopathies 11Huntington Disease 6Autoimmune Diseases of the Nervous System 4Autoimmune Diseases 29

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Myasthenia Gravis trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.